Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
Dow
AstraZeneca
Merck
Johnson and Johnson

Last Updated: December 5, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ARIKAYCE KIT

➤ Subscribe for complete access

« Back to Dashboard

All Clinical Trials for Arikayce Kit

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00558844 ↗ Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa Completed Insmed Incorporated Phase 1/Phase 2 2008-01-01 This is a study to determine the safety and tolerability of 28 days of daily dosing of 560 mg of Arikayce™ versus placebo and daily dosing of 70 mg and 140 mg of Arikayce™ versus placebo in patients who have Cystic fibrosis (CF) and chronic infection due to pseudomonas aeruginosa.
NCT00775138 ↗ Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa. Completed Insmed Incorporated Phase 2 2008-06-24 This is a study to determine the safety and tolerability of 28 days of daily dosing of two doses (280 mg and 560 mg) of Arikayce™ versus placebo in patients who have bronchiectasis and chronic infection due to Pseudomonas infection.
NCT00777296 ↗ Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™) Completed Insmed Incorporated Phase 1/Phase 2 2007-02-22 A major factor in the respiratory health of cystic fibrosis (CF) subjects is acquisition of chronic Pseudomonas aeruginosa infections. The infection rate with P. aeruginosa increases with age and by age 18 years, 80% of CF subjects in the U.S. are infected. Liposomal Amikacin for Inhalation (Arikace™) is a sterile aqueous liposomal suspension consisting of amikacin sulfate encapsulated in liposomes. This formulation of amikacin maximizes the achievable dose and delivery to the lungs of subjects infected via a nebulizer. Because liposome particles are small enough to penetrate and diffuse through sputum into the bacterial biofilm, they deposit drug in close proximity to the bacterial colonies, thus improving the bioavailability of amikacin at the infection site. The clinically achievable doses of amikacin in the LAI formulation can effectively increase the half-life of the drug in the lungs, and decrease the potential for systemic toxicity. LAI offers several advantages over current therapies in treating CF subjects with chronic infection caused by P. aeruginosa.
NCT01315236 ↗ Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 2012-04-19 The purpose of this study is to evaluate the efficacy, safety and tolerability of 84 days of daily dosing of 590 mg of LAI versus placebo in patients with treatment refractory NTM lung disease. The first part of the study is the 84-day double-blind phase to evaluate the primary and secondary endpoints.
NCT01315236 ↗ Liposomal Amikacin for Inhalation (LAI) for Nontuberculous Mycobacteria Completed Insmed Incorporated Phase 2 2012-04-19 The purpose of this study is to evaluate the efficacy, safety and tolerability of 84 days of daily dosing of 590 mg of LAI versus placebo in patients with treatment refractory NTM lung disease. The first part of the study is the 84-day double-blind phase to evaluate the primary and secondary endpoints.
NCT01315678 ↗ Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections Completed Insmed Incorporated Phase 3 2012-02-29 A major factor in the respiratory health of Cystic Fibrosis (CF) participants is the prevalence of chronic Pseudomonas aeruginosa (Pa) infections. The Pa infection rate in CF patients increases with age and by age 18 years approximately 85% of CF patients in the US are infected. Liposomal amikacin for inhalation (Arikayce™) was developed as a possible treatment for chronic infection due to Pa in CF patients. The purpose of this study is to determine whether Arikayce™ is effective in treating chronic lung infections caused by Pa in CF participants. The effectiveness, safety, and tolerability of Arikayce™ will be compared to Tobramycin TOBI®, an inhalation antibiotic already available for use.
NCT01316276 ↗ Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection Completed Insmed Incorporated Phase 3 2012-10-05 The purpose of this study is to evaluate the long term safety and tolerability of Liposomal Amikacin for Inhalation (LAI) 590 mg once daily (QD) in Cystic Fibrosis patients with chronic infection due to pseudomonas aeruginosa. This long-term, open-label, multi-cycle extension study enrolled subjects who had successfully completed study TR02-108, were compliant with the study protocol, and did not meet any of the listed study discontinuation criteria. The safety and tolerability of LAI were evaluated for up to approximately 2 years.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Arikayce Kit

Condition Name

Condition Name for Arikayce Kit
Intervention Trials
Cystic Fibrosis 4
Bronchiectasis 1
Mycobacterium Infections, Nontuberculous 1
Pseudomonas Aeruginosa Infection 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Arikayce Kit
Intervention Trials
Cystic Fibrosis 5
Infections 4
Fibrosis 4
Pseudomonas Infections 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Arikayce Kit

Trials by Country

Trials by Country for Arikayce Kit
Location Trials
United States 36
Hungary 5
Serbia 5
Poland 5
Canada 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Arikayce Kit
Location Trials
Pennsylvania 3
Minnesota 2
Maryland 2
Florida 2
Colorado 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Arikayce Kit

Clinical Trial Phase

Clinical Trial Phase for Arikayce Kit
Clinical Trial Phase Trials
Phase 3 2
Phase 2 3
Phase 1/Phase 2 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Arikayce Kit
Clinical Trial Phase Trials
Completed 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Arikayce Kit

Sponsor Name

Sponsor Name for Arikayce Kit
Sponsor Trials
Insmed Incorporated 7
National Institute of Allergy and Infectious Diseases (NIAID) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Arikayce Kit
Sponsor Trials
Industry 7
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Johnson and Johnson
Medtronic
Boehringer Ingelheim
Colorcon
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.